Recent 8-K filings for BCAX

• May 21, 2026, 5:04 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Bicara reports 31% 3-year OS with ficerafusp alfa + pembro in 1L R/M HPV-negative HNSCC

  Ficerafusp alfa 1500mg QW + pembrolizumab showed estimated 31% OS at 3 years, ~double retrospective standard of care OS (Vasiliadou et al. 2024).

• May 11, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Bicara Q1 net loss $56.2M; cash $539.8M; appoints new CMO and CCO; advances ficerafusp alfa

  Net loss of $56.2M for Q1 2026 vs $36.8M YoY; R&D expenses $47.5M, G&A $12.7M.

• March 30, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Bicara reports FY2025 net loss $138M; cash $414.8M; raises $161.8M in public offering

  Net loss Q4 2025 $37.4M, full year $138.0M vs $21.0M and $68.0M in 2024.

• February 26, 2026, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 2.02item 9.01 ◈ Material Agreements

  Bicara raises $161.8M in public offering; reports preliminary cash of $414.8M

  Net proceeds of ~$161.8M from offering of 7.175M shares at $16.00/sh and 2.2M pre-funded warrants.

• February 19, 2026, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Bicara Phase 1b data: ficerafusp alfa 2000mg Q2W shows 48% ORR, 26% CR in 1L HPV-negative HNSCC

  48% confirmed ORR and 26% complete response rate in 27 patients with 1L HPV-negative R/M HNSCC.

• January 12, 2026, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Bicara selects 1500 mg ficerafusp alfa dose for Phase 3 pivotal HNSCC study

  Selected 1500 mg QW ficerafusp alfa plus pembrolizumab as optimal dose for Phase 3 FORTIFI-HN01 in 1L HPV-negative R/M HNSCC.

• December 8, 2025, 6:59 PM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  Bicara reports 57% ORR in Phase 1b expansion; deeper responses at 1500mg dose; dose declaration on track for Q1 2026

  750mg ficerafusp alfa + pembrolizumab showed 57% confirmed ORR (17/30) with 10% complete response.

• November 10, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Bicara Therapeutics reports Q3 net loss of $36.3M, gets FDA Breakthrough Therapy Designation for ficerafusp alfa

  Net loss $36.3M in Q3 2025 vs $17.5M in Q3 2024; R&D expenses rose to $33.0M from $15.9M.

• August 12, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Bicara Therapeutics Q2 2025: Cash $436.6M, net loss $27.4M; Phase 1/1b data show 54% ORR in HNSCC

  Cash and equivalents $436.6M as of Jun 30, 2025, expected to fund operations into H1 2029.

• March 27, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Bicara Therapeutics reports Q4 net loss $21M, cash $489.7M; pivotal Phase 2/3 trial dosing started

  Net loss $21.0M in Q4 2024, $68.0M full year; vs $12.4M and $52.0M in 2023.

• November 12, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Bicara Therapeutics Q3 net loss $17.5M; cash $520.8M; pivotal HNSCC trial on track

  Cash and cash equivalents $520.8M as of Sep 30, 2024, funding operations into H1 2029.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.65 · Most common event other_material

5 positive 0 negative 11 neutral

source · BCAX on sec.gov